Top-News
Krebsforschung Kanada

Aptose Biosciences News

Aktie
WKN:  A3EENM ISIN:  CA03835T3091 US-Symbol:  APTO
1,41 €
+0,29 €
+25,89%
26.03.24 10:32:02
Handeln Depot/Watchlist
Aktienanzahl *
5,93 Mio.
Marktkapitalisierung *
6,70 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 06.06.2023

Aptose Biosciences News

26.01.24 - PR Newswire
Thinking about buying stock in Cipher Mining, SoundHound AI, Cellectar Biosciences, Bitdeer Technologies, or Aptose Biosciences?
Thinking about buying stock in Cipher Mining, SoundHound AI, Cellectar Biosciences, Bitdeer Technologies, or Aptose Biosciences? PR Newswire
09.04.23 - Small- & Micro Cap Investment
Innocan Pharma: Das therapeutische Potenzial von CBD für die Gesundheit von Frauen
Mehrere Studien haben bereits bewiesen, dass Männer und Frauen unterschiedlich häufig und mit unterschiedlichen Symptomen an bestimmten Krankheiten leiden und dass sie ...
19.08.14 - PR Newswire
Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders PR Newswire
07.08.14 - PR Newswire
Lorus Therapeutics to Present at the Canaccord Genuity 34th Annual Growth Conference
Lorus Therapeutics to Present at the Canaccord Genuity 34th Annual Growth Conference PR Newswire
28.07.14 - PR Newswire
Lorus Therapeutics Receives FDA Clearance of IND to Initiate LOR-253 Clinical Program in Patients with AML, MDS and other Blood Cancers
Lorus Therapeutics Receives FDA Clearance of IND to Initiate LOR-253 Clinical Program in Patients with AML, MDS and other Blood Cancers PR Newswire
15.07.14 - PR Newswire
Lorus Therapeutics Reports Results for the Fourth Quarter and Full Year Ended May 31, 2014
Lorus Therapeutics Reports Results for the Fourth Quarter and Full Year Ended May 31, 2014 PR Newswire
15.07.14 - PR Newswire
Lorus Therapeutics Proposes Name Change to "APTOSE BIOSCIENCES" and Share Consolidation for Potential NASDAQ Listing
Lorus Therapeutics Proposes Name Change to "APTOSE BIOSCIENCES" and Share Consolidation for Potential NASDAQ Listing PR Newswire
10.07.14 - PR Newswire
Lorus Therapeutics To Host Fourth Quarter and Year End 2014 Financial Results Conference Call and Webcast
Lorus Therapeutics To Host Fourth Quarter and Year End 2014 Financial Results Conference Call and Webcast PR Newswire
19.06.14 - PR Newswire
Lorus Therapeutics to Present at the 9th JMP Securities Healthcare Conference
Lorus Therapeutics to Present at the 9th JMP Securities Healthcare Conference PR Newswire
16.06.14 - PR Newswire
Lorus Therapeutics to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
Lorus Therapeutics to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference PR Newswire
10.06.14 - PR Newswire
Lorus Therapeutics Provides Update on Warrants
Lorus Therapeutics Provides Update on Warrants PR Newswire
27.03.14 - PR Newswire
IIROC Trade Resumption - LOR (all issues)
IIROC Trade Resumption - LOR (all issues) Canada NewsWire
02.12.13 - PR Newswire
Lorus Therapeutics Completes New Executive Management Team
Lorus Therapeutics Completes New Executive Management Team Avanish Vellanki and Gregory K. Chow Join as Chief Business Officer and Chief Financial Officer PR Newswire

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »